Viveve Medical, Inc. (VIVE) |
| 0.0003 0 (0%) 02-25 16:00 |
| Open: | 0.0001 |
| High: | 0.0003 |
| Low: | 0.0001 |
| Volume: | 2,330 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | Other OTC |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.08 |
| Resistance 1: | 0.06 |
| Pivot price: | 0.05 |
| Support 1: | 0.04 |
| Support 2: | 0.03 |
| 52w High: | 0.02 |
| 52w Low: | 0.0001 |
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
| EPS | -3.210 |
| Book Value | 0.110 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.058 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -309.73 |
| Return on Assets (ttm) | -62.1 |
| Return on Equity (ttm) | -211.0 |
Thu, 20 Feb 2025
Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence - ACCESS Newswire
Tue, 17 Jan 2023
Viveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence Trial - Yahoo Finance
Fri, 15 Oct 2021
Lessons from the Short-Squeeze Supernova Season - timothysykes.com
Tue, 05 May 2020
Viveve Medical raises $3.2m - MassDevice
Tue, 17 Oct 2017
Viveve wins Mexican clearance for Viveve system - MassDevice
Thu, 26 Feb 2026
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |